CN109419844B - Tibetan medicine composition for treating osteoarthritis pain - Google Patents

Abstract

The invention relates to a Tibetan medicine composition for treating osteoarthritis pain, which is prepared from the following raw material medicines: broom-corn millet, Qiaoguo Suba, rhizoma Drynariae, Tibetan vanilla, rhizoma Ligustici Chuanxiong, and Tibetan radix astragali. The invention also provides application of the Tibetan medicine composition. Its advantages are: the Tibetan medicine composition is a Tibetan medicine proved prescription developed by a traditional Chinese and western medicine combined diagnosis and treatment center in people hospitals in the Japanese Kai's law, is used for treating bone pain, particularly osteoarthritis pain, and is cheerful in result. The Tibetan medicine composition is based on the theory of 'three causes and five sources' of Tibetan medicine, and is compatible according to the principle of 'monarch, minister, assistant and guide', and the formed medicines are characteristic medicinal materials or genuine medicinal materials of the Tibet plateau, and have distinct national characteristics and regional colors.

Description

Tibetan medicine composition for treating osteoarthritis pain

Technical Field

The invention relates to the technical field of Tibetan medicines, in particular to a Tibetan medicine composition for treating osteoarthritis pain.

Background

Osteoarthritis (OA) refers to joint diseases caused by fibrosis, chap, ulcer and loss of joint cartilage due to various factors, and mainly shows pain and stiffness of joints. The disease is well developed in joints with heavy load and more movement, such as knee, spine (cervical vertebra and lumbar vertebra), hip, ankle, hand and other joints. The etiology is unclear, and the occurrence of the disease is related to age, obesity, inflammation, trauma, environment (particularly high cold environment), genetic factors and the like. The pathological features are degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic degeneration, joint marginal hyperosteogeny, synovial hyperplasia, joint capsular contracture, ligament relaxation or contracture, muscular atrophy and weakness, etc.

OA can be divided into primary and secondary categories. Primary OA usually occurs in the middle-aged and the elderly, has no clear systemic or local cause, and has a certain relationship with genetic and constitutional factors. Secondary OA can occur in young and old years and can be secondary to trauma, inflammation, joint instability, chronic and repeated cumulative strain or congenital diseases.

OA is common in the elderly, with more women than men. According to X-ray general survey, the incidence rate of the disease is up to 88 percent above 55 years old, and the disability rate is up to 53 percent. In plateau areas, the prevalence and disability rate of OA are obviously increased compared with those in plateau areas.

Therefore, OA is a common disease that seriously harms the health of people (especially people in the plateau area) and greatly impairs the quality of life of patients and their families.

The treatment of OA is comprehensive and includes non-drug, surgical treatments and the like, with the purpose of reducing or eliminating pain, correcting deformities, improving or restoring joint function, and improving quality of life.

Currently, drugs for treating OA fall into two broad categories: non-specific drugs and specific drugs. Non-specific drugs include antipyretic analgesics, NSAIDs, glucocorticoids, and narcotic analgesics. Specific drugs are also known as slow-acting drugs and are classified as: the medicine for improving symptoms: after being taken for a period of time, the composition can improve osteoarticular symptoms, inhibit pain and release of tissue factors to block the progress of disease course, and comprises glucosamine sulfate, diacerein, chondroitin sulfate and hyaluronic acid; ② a medicine for improving structure: can delay or reverse the damage of joint cartilage, protect normal cartilage and observe the change of joint structure by using proper imaging method.

Reduction or elimination of pain is a primary goal of OA treatment. In the drug treatment, NSAIDs are the first choice of drugs, and have better treatment effects on inflammatory manifestations of OA, such as arthralgia, swelling, hydrops and limited mobility. However, these drugs have many toxic and side effects, and can cause drug resistance after long-term use. The major toxic side effects of NSAIDs include: adverse reactions in gastrointestinal tract: adverse gastrointestinal reactions of NSAIDs are mainly manifested by upper gastrointestinal bleeding caused by gastric and duodenal ulcers. According to the statistics of the FDA in the United states, the incidence rate of gastrointestinal ulcer, bleeding and perforation is 1-2% for patients taking NSAIDs for 3 months, and the incidence rate is 2-5% for patients taking NSAIDs for 1 year. The higher proportion of elderly people who develop life-threatening gastric and duodenal perforation and bleeding. ② adverse reaction of kidney: NSAIDs inhibit prostaglandin synthesis, so that renal perfusion cannot be maintained, and sodium and water retention, hyperkalemia, even acute renal insufficiency, interstitial nephritis, renal necrosis, etc. may occur. ③ other adverse reactions: NSAIDs also have adverse effects on the central nervous system, the blood system, the skin, the liver, etc., which are often dose-related; few patients develop allergic reactions, such as rubella, allergic rhinitis, asthma, regardless of dose. Common central nervous symptoms include lethargy, absentmindedness, mental depression, and the like. After 15% of patients take NSAIDs, the serum transaminase level is increased, bilirubin is increased, and the thromboplastin time is prolonged. Serious adverse events such as agranulocytosis, pernicious anemia, etc. can occur in the blood system.

The slow-acting medicine and cartilage protective agent for treating OA comprise sodium hyaluronate, glucosamine and Tc-MDP injection which is autonomously developed in China and has multiple target points to improve the state of OA, and have certain curative effect on delaying the progress of OA diseases. However, so far, even though the pain of the disease is effectively controlled, the invention is still a difficult point of clinical treatment at home and abroad without inventing or discovering new drugs to completely change and prevent the disease.

In the plateau of Tibet, high cold and oxygen deficiency are important reasons for high incidence of OA in Tibet. Numerous studies have shown that excessive cold stimulation induces pain and cold sensation hypersensitivity. The long-term cold stimulation environment can also cause nerve damage and neuropathic pain. Thus, plateau OA is a special type of OA, the pain of which is the result of the superposition of inflammatory and neuropathic pain, with marked regional characteristics. However, at present, the treatment for plateau OA at home and abroad, including the treatment for plateau OA pain, still adopts the treatment method in plain areas, and lacks a specific diagnosis and treatment scheme for plateau areas, so that the clinical curative effect is greatly reduced.

In conclusion, the treatment of chronic pain is still a difficult problem for the clinical treatment of OA at home and abroad. In the case of high altitude OA pain, particularly, in the absence of specific therapeutic approaches, related studies are still in the blank stage. Therefore, the search for effective, stable and safe treatment methods and drugs for altitude OA is a problem to be solved in the research field of OA.

The history of the Tibetan medicine for treating the arthritis pain is over thousands of years, and the Tibetan medicine has distinct characteristics and definite curative effect. The third secret formula book (Jiaadai) of the four medical classics (residence society) of Tibetan medicine for osteoarthritis has two chapters of "killing gram" and "planting cloth" diseases. It is considered to be related to damp, cold and cold feeling in the residence, cold diet and excessive fat. Under the condition, the functions of dragon, red bara and bacon which are responsible for digestion are influenced, and the diet can not be refined to generate yellow water, and the yellow water is transported to joint cavities, muscles and white veins by the dragon, thereby causing the diseases.

The Tibetan medicine of the broom-corn-jade-like mackerel traditional Chinese medicine is named as rhodiola rosea, is a rare wild plant growing in high altitude, high cold, large temperature difference and pollution-free environment and vigorous in vitality, and is one of common medicines of Tibetan medicine and internationally recognized plant adaptogen. The rhodiola rosea can grow in extremely severe and changeable natural environment, shows that the rhodiola rosea has activities of cold resistance, radiation resistance and the like, also means that the rhodiola rosea is genetically adapted to severe environment with severe cold and change and has special adaptive substances which are not possessed by other plants. The efficacy of rhodiola rosea has been recorded very early in famous Tibetan medicine classic "the four medical classics" and "Tibetan medicine reference". Rhodiola root has obvious pharmacological activity and has a plurality of pharmacological actions such as oxidation resistance, inflammation diminishing, low temperature resistance and the like. The salidroside is an extract of rhodiola rosea, is a main effective component of rhodiola rosea playing a role, and participates in regulation and control of an inflammation signal transduction pathway. The domestic research finds that the rhodiola rosea has the capacity of enhancing the low temperature resistance of mice. After being given by the rhodiola sachalinensis, the healthy mice are placed in a refrigerator at the temperature of-5 ℃, the death number is remarkably reduced, and the rhodiola sachalinensis can remarkably improve the cold resistance of the mice. Recently, human airway epithelial cells (HBE16) were studied by cold temperature exposure^[10]Salidroside is shown to exert its protective effects by inhibiting the activation of the transient receptor potential melastatin8 channel (TRPM8) to reduce excessive stimulation of cold-induced Mucin (MUC), but there is no in vivo evidence.

The Tibetan medicine Qiaoguo Suba traditional Chinese medicine is named as snow lotus, belongs to saussurea of Compositae, is originally recorded in Tibetan medicine 'Yuekang medicine' in Tibetan medicine literature, is a common regional medicine in plateau cold zone areas such as Tibet, Xinjiang and Qinghai, and has the functions of dispelling cold and removing dampness, activating blood and stimulating the menstrual flow, resisting inflammation, relieving pain and the like. In recent years, with the continuous and intensive research, snow lotus herb has become a new important variety for anti-inflammation and analgesia. Generally, the main active ingredients in saussurea involucrate are flavonoids, saussurea involucrate polysaccharide and alkaloid, wherein the main active ingredients are flavonoids. But the mechanism of action and the target are not clear.

Chinese patent document CN106620070A discloses a pharmaceutical composition for treating osteoarthropathy, which is prepared from the following raw materials: folium Artemisiae Argyi, ramulus Cinnamomi, rhizoma Ligustici Chuanxiong, radix Angelicae sinensis, Saviae Miltiorrhizae radix, stigma croci Sativi, herba Saussureae Involueratae, and radix Rhodiolae. Chinese patent document CN104474124A discloses a medicinal liquor for treating rheumatic arthritis, which is prepared from the following raw materials: snow lotus herb, pilose antler, safflower, lucid ganoderma, rhodiola rosea, medlar and white spirit. Chinese patent document CN103330927A discloses a medicine for treating osteoarthritis, which is prepared from the following raw material medicines: fructus Lycii, Eucommiae cortex, rhizoma Curculiginis, radix Puerariae, fructus Chaenomelis, rhizoma Drynariae, radix astragali, semen Ziziphi Spinosae, radix Rhodiolae, radix aucklandiae, pericarpium Citri Tangerinae, colla Corii Asini, Carthami flos, radix Cyathulae, herba Pyrolae, semen Sesami Niger, rhizoma Dioscoreae, Poria, radix Saposhnikoviae, rhizoma Zingiberis recens, flos Lonicerae, rhizoma Ligustici Chuanxiong, Saviae Miltiorrhizae radix, herba Lycopodii, and rhizoma Polygoni Cuspidati.

Disclosure of Invention

The invention aims to provide a Tibetan medicine composition for treating osteoarthritis pain, aiming at the defects in the prior art.

The second purpose of the invention is to provide the application of the Tibetan medicine composition.

In order to achieve the purpose, the invention adopts the technical scheme that: a Tibetan medicine composition for treating osteoarthritis pain is prepared from the following raw material medicines in parts by weight: 12-18 parts of broom cypress, 12-18 parts of Qiaoguo Suba, 12-18 parts of rhizoma drynariae, 10-14 parts of Tibetan vanilla, 10-14 parts of ligusticum wallichii and 8-12 parts of Tibetan astragalus.

Preferably, the Tibetan medicine composition is prepared from the following raw material medicines in parts by weight: 14-16 parts of broom cypress, 14-16 parts of Qiaoguo Suba, 14-16 parts of rhizoma drynariae, 11-13 parts of Tibetan vanilla, 11-13 parts of ligusticum wallichii and 9-11 parts of Tibetan astragalus.

Preferably, the Tibetan medicine composition is prepared from the following raw material medicines in parts by weight: 15 parts of broom cypress, 15 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 12 parts of rhizoma ligustici wallichii and 10 parts of Tibetan astragalus.

In order to achieve the second object, the invention adopts the technical scheme that: the Tibetan medicine composition is applied to the preparation of the medicine for treating osteoarthritis.

The osteoarthritis is plateau knee osteoarthritis.

The medicament dosage form is an oral preparation.

The medicament is powder.

The invention has the advantages that:

1. the Tibetan medicine composition (Liuwei Balong powder) is a Tibetan medicine proved prescription developed by a traditional Chinese and western medicine combined diagnosis and treatment center in people hospitals in the Japanese Kai nationality, is used for treating bone pain, particularly osteoarthritis pain, and is cheerful in result. The Liuwei Balong powder is prepared by taking the Tibetan medicine theory of 'three causes and five sources' as a basis and carrying out compatibility according to the principle of 'monarch, minister, assistant and guide', and the formed medicines are characteristic medicinal materials or genuine medicinal materials of Qingcang plateau and have distinct national characteristics and regional colors.

2. The broom cypress fruit and broom cypress fruit contained in the Tibetan medicine composition of the invention have the effects of tonifying kidney and qi, removing blood stasis and dredging collaterals, and are monarch medicines; the Qiaoguo Suba has the effects of warming kidney, dispelling cold, relieving swelling and pain, and tonifying kidney, strengthening bone, healing wound and relieving pain of rhizoma drynariae, and is used as a ministerial drug together; the Tibetan vanilla and the chuanxiong rhizome, rhizoma ligustici wallichii, pungent in flavor, have the effects of dispelling wind-damp and relieving arthralgia, and also have the effect of removing cold and cool nature of roman, and are used as adjuvant drugs; tibetan Huang Qi can tonify qi and warm yang, and serves as a guiding drug to assist the efficacy of drugs. The medicines are combined to play the effects of dispelling cold, dredging collaterals, tonifying kidney, activating blood circulation, eliminating arthralgia and relieving pain.

Detailed Description

The following examples are provided to illustrate specific embodiments of the present invention.

EXAMPLE 1 Tibetan medicinal composition

15 parts of broom cypress, 15 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 12 parts of rhizoma ligustici wallichii and 10 parts of Tibetan astragalus.

EXAMPLE 2 Tibetan medicinal composition

12 parts of broom cypress, 14 parts of Qiaoguo Suba, 18 parts of rhizoma drynariae, 10 parts of Tibetan vanilla, 10 parts of ligusticum wallichii and 10 parts of Tibetan astragalus.

EXAMPLE 3 Tibetan medicinal composition

13 parts of broom cypress, 15 parts of Qiaoguo Suba, 17 parts of rhizoma drynariae, 11 parts of Tibetan vanilla, 10 parts of ligusticum wallichii and 10 parts of Tibetan astragalus.

EXAMPLE 4 Tibetan medicinal composition

14 parts of broom cypress, 16 parts of Qiaoguo Suba, 16 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 11 parts of ligusticum wallichii and 9 parts of Tibetan astragalus.

EXAMPLE 5 Tibetan medicinal composition

15 parts of broom cypress, 12 parts of Qiaoguo Suba, 16 parts of rhizoma drynariae, 13 parts of Tibetan vanilla, 11 parts of ligusticum wallichii and 9 parts of Tibetan astragalus.

EXAMPLE 6 Tibetan medicinal composition

16 parts of broom cypress, 13 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 14 parts of Tibetan vanilla, 12 parts of ligusticum wallichii and 11 parts of Tibetan astragalus.

EXAMPLE 7 Tibetan medicinal composition

17 parts of broom cypress, 14 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 10 parts of Tibetan vanilla, 12 parts of ligusticum wallichii and 11 parts of Tibetan astragalus.

EXAMPLE 8 Tibetan medicinal composition

18 parts of broom cypress, 15 parts of Qiaoguo Suba, 14 parts of rhizoma drynariae, 11 parts of Tibetan vanilla, 13 parts of ligusticum wallichii and 12 parts of Tibetan astragalus.

Example 9 Tibetan medicinal composition

14 parts of broom cypress, 16 parts of Qiaoguo Suba, 14 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 13 parts of ligusticum wallichii and 12 parts of Tibetan astragalus.

Example 10 Tibetan medicinal composition

15 parts of broom cypress, 17 parts of Qiaoguo Suba, 13 parts of rhizoma drynariae, 13 parts of Tibetan vanilla, 14 parts of ligusticum wallichii and 8 parts of Tibetan astragalus.

EXAMPLE 11 Tibetan medicinal composition

16 parts of broom cypress, 18 parts of Qiaoguo Suba, 12 parts of rhizoma drynariae, 14 parts of Tibetan vanilla, 14 parts of rhizoma ligustici wallichii and 8 parts of Tibetan astragalus.

EXAMPLE 12 powder preparation

The Tibetan medicine composition of the embodiment 1 to 11 is sent into a grinder to be ground into fine powder, sieved, and then the sieved fine powder is put into a mixing stirrer to be fully mixed to obtain powder.

Example 13 granules

The Tibetan medicinal composition of the examples 1 to 11 is decocted in water for 3 times, the filtrates are combined and concentrated to a clear paste with a relative density of 1.1. Adding ethanol into the fluid extract, standing for 24 hours, filtering, recovering ethanol, and concentrating to obtain a thick paste with a relative density of 1.2. Spray drying the soft extract to obtain dry extract fine powder. Adding dextrin into the dry extract fine powder, mixing, granulating by conventional method, drying, and making into granule.

EXAMPLE 14 dispersible tablets

The Tibetan medicinal composition of the examples 1 to 11 is decocted in water for 3 times, the filtrates are combined and concentrated to a clear paste with a relative density of 1.1. Spray drying the fluid extract to obtain dry extract fine powder. Mixing the dry extract fine powder with sodium carboxymethyl starch and microcrystalline cellulose, granulating by conventional method, drying, adding magnesium stearate and silicon dioxide, mixing, tabletting by conventional method, and making into dispersible tablet.

EXAMPLE 15 capsules

The Tibetan medicinal composition of the examples 1 to 11 is decocted in water for 3 times, the filtrates are combined and concentrated to a clear paste with a relative density of 1.15. Spray drying the fluid extract to obtain dry extract fine powder. Adding magnesium stearate and pulvis Talci, mixing, adding hollow capsule by conventional method, and making into capsule.

EXAMPLE 16 pellets

The Tibetan medicinal composition of the examples 1 to 11 is decocted in water for 3 times, the filtrates are combined and concentrated to a clear paste with the relative density of 1.18. Spray drying the fluid extract to obtain fine powder. Adding appropriate amount of water or/and yellow wine, and making into watered pill. Or adding appropriate amount of ethanol and soybean oil to make soft mass, making into pill with pellet making machine, drying, sieving, and making into pellet. Or making dripping pill with polyethylene glycol as matrix and dimethyl silicone oil as condensate.

Example 17 oral liquid

The Tibetan medicinal composition of the examples 1 to 11 is decocted in water for 3 times, the filtrates are combined and concentrated to a clear paste with a relative density of 1.1. Adding ethanol into the fluid extract, standing for 24 hours, filtering, recovering ethanol, and concentrating to obtain a thick paste with a relative density of 1.2. Dissolving stevioside in pure water by conventional method, adding sodium benzoate and purified water, mixing with the soft extract, and making into oral liquid.

Example 18 soup

The Tibetan medicinal composition of examples 1-11 is decocted in water to obtain a decoction.

EXAMPLE 19 clinical trial

1 data and method

1.1 case selection

1.1.1 diagnostic criteria

The diagnosis of the knee osteoarthritis meets the relevant standards in the Chinese expert consensus on diagnosis and treatment of the knee osteoarthritis. Plateau knee osteoarthritis refers to knee osteoarthritis patients who live in the Tibet plateau for a long time.

1.1.2 inclusion criteria

Firstly, the diagnosis meets the standard; ② it is possible to exclude the effects of other treatments already in use or in use, including delayed effects.

1.1.3 exclusion criteria

(ii) those who have already been treated by other treatment methods for this disease; ② the treatment front alanine Aminotransferase (ALT) and creatinine (Cr) exceed the upper limit of the normal value by 2 times, or other complications affect the curative effect analysis.

1.2 general data

The 72 cases are knee osteoarthritis patients diagnosed and treated in departments such as orthopedics and traumatology, combined traditional Chinese and western medicine and the like and wards of people hospitals in the Min-Ri-Ke city in 2011-2015 for 11 months. Wherein, 44 men and 28 women; age 33-74 years, median age 56 years.

1.3 methods of treatment

Six-ingredient barlong powder (broom corn tulip 15 g, Qiaoguo Suba 15 g, drynaria 15 g, Tibetan vanilla 12 g, Ligusticum wallichii 12 g, Tibetan astragalus root 10g, grinding into fine powder together), one dose per day, three times with warm boiled water for oral administration. 3 months is a treatment course, and the treatment effect of the patient is analyzed and evaluated after one to two treatment courses.

1.4 Observation items and methods

The clinical curative effect of the patients is evaluated according to relevant literature standards after reaching the specified treatment course.

(1) Knee joint pain: pain scores were obtained by Visual Analogue Scale (VAS), with 0 being no pain and 10 being most painful.

(2) Knee joint function: and (4) scoring the knee joint function by adopting a Lysholm knee joint scoring system. The system has 7 items, and is full of 100 points, including difficulty squatting (5 points), lameness (5 points), pain (25 points), difficulty going up and down stairs (10 points), support requirement (5 points), unstable joints (25 points), presence or absence of interlocking (15 points), and swelling (1O points). The higher the score, the better the joint function, more than 84 points are normal, 66-84 points are good, and less than 66 points are poor.

2 results

2.1 clinical efficacy

After 72 patients are treated by the six-ingredient Croton powder for one to two treatment courses, 63 patients are improved or obviously improved before treatment, and the total effective rate is 87.5 percent. See table 1.

TABLE 1 statistics of clinical efficacy (example)

Method of treatment	n	Show effect	Is effective	Invalidation	Total effective rate
						Six-ingredient barlong powder	72	28	35	9	87.5％

2.2 adverse reactions

In the course of taking the six-ingredient baryong powder, 5 patients suffered from epigastric discomfort and/or anorexia (the symptoms disappeared after eating by oral administration), 2 patients suffered from constipation, 1 patient suffered from insomnia aggravated earlier, and 1 patient suffered from mild liver dysfunction (the history of alcoholic hepatitis existed before). No obvious renal dysfunction and clinically significant electrocardiogram change are observed in the medication process of all cases. No serious adverse events were seen.

Example 20 animal testing

1 materials of the experiment

1.1 Experimental animals

The weight of 100 New Zealand white rabbits is 1.8-2.2 kg, the male and female rabbits are not limited, and the standard feed is suitable for feeding. The groups were randomly divided into 10 groups of 10 individuals.

1.2 Molding method

Using pentobarbital sodium (40mg/kg dose), anesthesia was performed, and molding was performed according to the Hulth method except for the normal group.

1.3 Experimental methods

Group A: normal group. No molding was performed.

Group B: and (4) model groups. Gavage with 0.9% physiological saline, 100 ml/day for 8 weeks.

Group C: bone-strengthening joint pill. Making into water solution, and irrigating with 100 ml/day (containing bone strengthening joint pill 10g) for 8 weeks.

Group D: example 1. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

Group E: example 7. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

And F group: 10 parts of broom cypress, 9 parts of Qiaoguo Suba, 10 parts of rhizoma drynariae, 20 parts of Tibetan vanilla, 25 parts of ligusticum wallichii and 18 parts of Tibetan astragalus. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

Group G: 15 parts of broom-corn millet, 15 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 12 parts of ligusticum wallichii, 10 parts of Tibetan astragalus, 15 parts of saffron, 12 parts of salvia miltiorrhiza and 15 parts of divaricate saposhnikovia root. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

Group H: 15 parts of broom cypress, 15 parts of Qiaoguo Suba and 15 parts of rhizoma drynariae. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

Group I: 15 parts of broom cypress, 15 parts of rhizoma drynariae, 12 parts of Tibetan vanilla and 10 parts of Tibetan astragalus. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

Group J: 15 parts of broom cypress, 15 parts of Qiaoguo Suba and 12 parts of ligusticum wallichii. Decocting in water to obtain decoction, and intragastrically administering for 8 weeks at a dosage of 100 ml/day (corresponding to 10g of crude drug).

1.4 Observation index

Determination of serum Nitric Oxide (NO): anaesthetizing with 1% thiopentan, laying the rabbit on the femoral artery to take blood, standing for 30 minutes, placing the rabbit in a low-temperature centrifuge, centrifuging, taking the serum above, and detecting the serum NO according to the requirements of the kit specification.

Measuring the content of NO and IL-1 beta in the joint fluid: after the experimental animal is sacrificed, the joint capsule is cut under the aseptic condition, 0.5ml of joint synovial fluid is extracted, and the content of NO and IL-1 beta is measured according to the requirement of the kit specification.

And (3) safety detection: after the experimental animals are sacrificed, the morphology of organs such as heart, liver, kidney, lung, testis and the like of each group of rabbits is immediately observed by naked eyes.

2 results of the experiment

2.1 serum NO measurements the results are shown in Table 2.

TABLE 2 determination of serum NO content

Group of	Serum NO (μmol/L)
		Group A	115.08±33.87
Group B	160.13±50.25
		Group C	126.04±26.31
Group D	121.39±27.33
		Group E	122.89±27.42
Group F	128.37±28.93
		Group G	139.41±36.11
Group H	143.33±37.29
		Group I	144.09±39.01
J group	146.56±38.22

2.2 measurement of NO content in synovial fluid, the results are shown in Table 3.

TABLE 3 determination of the NO content of synovial fluid

Group of	Joint fluid NO (mu mol/L)
		Group A	31.43±6.55
Group B	64.71±9.25
		Group C	41.04±2.49
Group D	38.74±2.33
		Group E	39.13±2.41
Group F	42.47±2.69
		Group G	49.62±7.32
Group H	51.36±8.01
		Group I	53.55±7.43
J group	54.27±7.69

2.3 determination of IL-1. beta. content in synovial fluid, the results are shown in Table 4.

TABLE 4 determination of IL-1. beta. content in synovial fluid

Group of	Joint fluid IL-1 beta (pg/ml)
		Group A	13.86±2.71
Group B	33.26±4.15
		Group C	22.39±3.40
Group D	19.48±3.11
		Group E	20.17±3.37
Group F	24.18±3.87
		Group G	28.29±3.62
Group H	30.71±3.67
		Group I	29.67±3.64
J group	31.03±3.96

2.4 safety test results: no obvious abnormal change is observed in organs such as heart, liver, lung, kidney, testis and the like of the rabbit through naked eye observation, and no obvious pathological change is observed in the section.

The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.

Claims (7)

1. The Tibetan medicine composition for treating osteoarthritis pain is characterized by being prepared from the following raw material medicines in parts by weight: 12-18 parts of broom cypress, 12-18 parts of Qiaoguo Suba, 12-18 parts of rhizoma drynariae, 10-14 parts of Tibetan vanilla, 10-14 parts of ligusticum wallichii and 8-12 parts of Tibetan astragalus.

2. The Tibetan medicine composition of claim 1, wherein the Tibetan medicine composition is prepared from the following raw material medicines in parts by weight: 14-16 parts of broom cypress, 14-16 parts of Qiaoguo Suba, 14-16 parts of rhizoma drynariae, 11-13 parts of Tibetan vanilla, 11-13 parts of ligusticum wallichii and 9-11 parts of Tibetan astragalus.

3. The Tibetan medicine composition of claim 1, wherein the Tibetan medicine composition is prepared from the following raw material medicines in parts by weight: 15 parts of broom cypress, 15 parts of Qiaoguo Suba, 15 parts of rhizoma drynariae, 12 parts of Tibetan vanilla, 12 parts of rhizoma ligustici wallichii and 10 parts of Tibetan astragalus.

4. Use of a Tibetan medicinal composition as claimed in any one of claims 1 to 3 in the manufacture of a medicament for the treatment of osteoarthritis.

5. The use of claim 4, wherein the osteoarthritis is high altitude knee osteoarthritis.

6. The use according to claim 4, wherein the pharmaceutical dosage form is an oral formulation.

7. The use of claim 6, wherein said pharmaceutical dosage form is a powder.